On October 9, Recursion Pharmaceuticals, Inc. rose 8.1% in regular trading, trading at $4.265/share, with turnover of $61.01 million.

The stock's movement comes amid ongoing market debate over its revised collaboration agreement with Tempus AI. The amended terms replaced up to $84 million in discretionary payments over two years with $42 million in committed payments over three years, and removed Recursion's right to terminate the agreement for convenience. Some investors view the extended, more predictable commitment as strategically positive, while others remain concerned about reduced financial flexibility. Concurrent insider selling, including a director sale of 50,000 shares on October 6, has added to mixed sentiment.

Recursion Pharmaceuticals operates a clinical-stage TechBio platform integrating over 50 petabytes of proprietary data through its recursive operating system to industrialize drug discovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)